Study of IK-595 in RAS- or RAF-altered Advanced Tumors

"This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit."

FIH - First In Human trial

150 Patients

Opened Dec 2023

NOTE: All interventional trials involve risk. 

So please consult with your oncology team as well as ask questions of the trial research team about patient responses or any side effects. 

TRIAL LINK:

https://clinicaltrials.gov/study/NCT06270082?term=NCT06270082&rank=1

Trial description: A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.

https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS3185?fbclid=IwY2xjawFm7ghleHRuA2FlbQIxMAABHRYe8bGhU1jxlOSN_PsGRPFL9slZ81_oW81BwLu5gJoWO5pbtnu4GDuiFg_aem_zRV_lsGZjjndbSrru288VQ

Preclinical Slides from the Targeting RAS conference, 2023.

https://ikenaoncology.com/wp-content/uploads/2023/03/IK595_TargetingRAS23_Michelle_Zhang_Final.pdf

More webinar presentations are available on the Ikena Oncology website

https://ir.ikenaoncology.com/events-and-presentations

September 10, 2024 corporate presentation (20 slides)

https://ir.ikenaoncology.com/static-files/17352b85-0b60-4af4-bb33-52c19492ff76

Poster for Preclinical Research (see screenshot)

https://ikenaoncology.com/wp-content/uploads/2023/10/EORTC-IK-595-Poster.pdf?fbclid=IwY2xjawFm7epleHRuA2FlbQIxMAABHc9FfnDErHzxSZl24VRtVLBuk35EcgPan5_4pvb7IRmL0oJsqLetbu8NhQ_aem_cBOFvUOTioRpK8HRG31EIw

Link to Post in the KRAS KICKERS Facebook group:

https://www.facebook.com/groups/kraskickers/posts/957470925616627